Experimental Drug Reverses Severe Fatty Liver Disease by Repairing the Gut
3 Articles
3 Articles
Experimental drug reverses severe fatty liver disease by repairing the gut
An experimental drug called DT-109 reversed severe fatty liver disease in animal studies by repairing the gut and preventing harmful toxins from damaging the liver. The discovery could open the door to a new class of treatments for MASH and potentially other diseases tied to gut health.
New drug candidate treats severe fatty liver disease by improving gut health
From News Medical Researchers discovered that a potential drug developed at Michigan Medicine treats severe fatty liver disease by improving gut health, according to a study published in The Journal of Clinical Investigation. The glycine-based tripeptide, DT-109, reversed metabolic dysfunction-associated steatohepatitis (MASH) in animal models by disrupting a disease-driving pathway that links the gut and liver.
Researchers at Michigan Medicine have developed a new experimental compound, called DT-109, which has demonstrated the ability to reverse severe fatty liver disease in animal models. The study, published in The Journal of Clinical Investigation, suggests that the approach of restoring gut health may be an innovative strategy for treating metabolic steatosis-associated steatosis (MASH). Mechanism of action of DT-109: DT-109 works by interrupting …
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
